Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Xuecai Xue"'
Autor:
Xingxian Luo, Xin Du, Lin Huang, Qixiang Guo, Xufeng Lv, Cen Wang, Haopeng Liu, Yue Zhou, Xuecai Xue, Zhuangqi Li, Jingwen Liu, Shein-Chung Chow, Yue Yang
Publikováno v:
EClinicalMedicine, Vol 63, Iss , Pp 102177- (2023)
Summary: Background: Accelerated approval (AA) of novel anticancer drugs based on surrogacy has attracted considerable concern globally. China National Medical Products Administration (NMPA) also established a similar conditional approval (CA) progra
Externí odkaz:
https://doaj.org/article/7835359a841d46439270663cc2de348a
Autor:
Xingxian Luo, Xin Du, Lin Huang, Qixiang Guo, Ruijie Tan, Yue Zhou, Zhuangqi Li, Xuecai Xue, Taifeng Li, Kaidi Le, Feng Qian, Shein-Chung Chow, Yue Yang
Publikováno v:
The Lancet Regional Health. Western Pacific, Vol 32, Iss , Pp 100670- (2023)
Summary: Background: Affordability to novel anticancer drugs has become a major health issue in China. It is encouraging to note that China initiated its drug regulatory reform and national price negotiation policies since 2015. As a growing number o
Externí odkaz:
https://doaj.org/article/8f04d5b36a9a47c5a3c46d0997c20b89
Autor:
Lizong Li, Wenpei Wang, Xuecai Xue, Wenjuan Miao, Xiaofan Liu, Xiaoling Cheng, Xiaoling Wang, Lin Huang, Yufei Feng
Publikováno v:
Intelligent Pharmacy; Dec2023, Vol. 1 Issue 4, p274-279, 6p
Autor:
Xingxian Luo, Xin Du, Lin Huang, Qixiang Guo, Xufeng Lv, Miao Wang, Haopeng Liu, Yue Zhou, Xuecai Xue, Zhuangqi Li, Jingwen Liu, Shein-Chung Chow, Yue Yang
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::834f366ebd2bce695660cc4374cf0a4e
https://doi.org/10.2139/ssrn.4429945
https://doi.org/10.2139/ssrn.4429945
Autor:
Ze Yu, Haiyang Zhao, Liping Ma, Xuecai Xue, Changqing Yang, Taifeng Li, Lin Huang, Xingxian Luo, Wanyu Feng, Na Li
Publikováno v:
Xenobiotica. 49:753-761
1. Imatinib is widely used for the treatment of hematologic malignancies. It is common that imatinib is clinically co-prescribed with azole antifungal agents since these patients are more prone to invasive antifungal infection. The present study was
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76bbb369e45e314f97bb62f92fbbb724
https://doi.org/10.1080/00498254.2018.1473662
https://doi.org/10.1080/00498254.2018.1473662
Publikováno v:
Current drug metabolism. 21(13)
Background: Dasatinib, as an oral multi-targeted inhibitor of BCR-ABL and SRC family kinases, has been widely used for the treatment of Philadelphia Chromosome Positive Leukemias in imatinib-acquired resistance and intolerance. The study aimed to dev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::baea242d5d54abdbe4d2dbb8ae2a53a8
https://pubmed.ncbi.nlm.nih.gov/33092505
https://pubmed.ncbi.nlm.nih.gov/33092505